AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · IEX Real-Time Price · USD
4.660
-1.880 (-28.75%)
Apr 19, 2024, 4:00 PM EDT - Market closed
Company Description
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.
It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.
AEON Biopharma, Inc. is based in Irvine, California.
AEON Biopharma, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Marc Forth |
Contact Details
Address: 5 Park Plaza, Suite 1750 Irvine, California 92614 United States | |
| Phone | (949) 354-6499 |
| Website | aeonbiopharma.com |
Stock Details
| Ticker Symbol | AEON |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001837607 |
| CUSIP Number | 00775E102 |
| ISIN Number | US00791X1000 |
| Employer ID | 85-3940478 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marc Forth | President, Chief Executive Officer and Director |
| Dr. Chad K. Oh M.D. | Chief Medical Officer |
| Peter A. Reynolds CPA | Chief Financial Officer |
| Alex Wilson | Executive Vice President, Chief Legal Officer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 17, 2024 | 8-K | Current Report |
| Apr 15, 2024 | 8-K | Current Report |
| Apr 2, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 1, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 29, 2024 | 10-K | Annual Report |
| Mar 29, 2024 | 10-Q/A | [Amend] Quarterly report |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 8-K | Current Report |